Loading clinical trials...
Loading clinical trials...
Plasma Adsorption in Patients With Confirmed COVID-19 Infection
Conditions
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Locations
7
United States
University of Arkansas for Medical Sciences (UAMS)
Little Rock, Arkansas, United States
UNM Health Science Center
Albuquerque, New Mexico, United States
Providence Portland Medical Center
Portland, Oregon, United States
Reading Hospital
West Reading, Pennsylvania, United States
UT Southwestern/Clements Hospital
Dallas, Texas, United States
UTMB
Galveston, Texas, United States
Start Date
May 20, 2020
Primary Completion Date
November 26, 2021
Completion Date
April 1, 2022
Last Updated
April 11, 2022
NCT04068012
NCT06213168
NCT07451977
NCT07504731
NCT06703073
NCT06189924
Lead Sponsor
Marker Therapeutics AG
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions